Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Veracyte Inc (NQ: VCYT )

22.95 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 22.95
Bid (Size) 9.230 (1)
Ask (Size) 27.24 (1)
Prev. Close 22.95
Today's Range 22.95 - 22.95
52wk Range 18.61 - 29.35
Shares Outstanding 67,473,870
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
The 3 Best Personalized Nutrition Stocks to Buy Now
Explore personalized nutrition stocks capitalizing on AI, machine learning and genetic profiling to provide targeted dietary solutions. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Veracyte to Release Second Quarter 2024 Financial Results on August 6, 2024
From Veracyte, Inc.
Via Business Wire

Performance

YTD
-16.24%
-16.24%
1 Month
+7.95%
+7.95%
3 Month
+13.67%
+13.67%
6 Month
-9.50%
-9.50%
1 Year
-11.22%
-11.22%

More News

Read More
Trading SMID Biotech Stocks In A Volatile Market
Via Talk Markets
Cathie Wood-Lead Ark Invest Dumps $7.6M Worth Of Robinhood Shares Amid GameStop Buzz, Bitcoin Choppiness
Via Benzinga
A Glimpse Into The Expert Outlook On Veracyte Through 4 Analysts
Via Benzinga
Recap: Veracyte Q4 Earnings
Via Benzinga
Earnings Outlook For Veracyte
Via Benzinga
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors
From Veracyte, Inc.
Via Business Wire
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and Cancer
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in Upcoming Investor Conferences
From Veracyte, Inc.
Via Business Wire
VCYT Stock Earnings: Veracyte Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Veracyte Announces First Quarter 2024 Financial Results
From Veracyte, Inc.
Via Business Wire
14 Studies Presented at AUA 2024 Show Decipher Tests’ Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease Understanding
From Veracyte, Inc.
Via Business Wire
Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024
From Veracyte, Inc.
Via Business Wire
New Study Shows Veracyte’s Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance
From Veracyte, Inc.
Via Business Wire
Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024
From Veracyte, Inc.
Via Business Wire
Cathie Wood's Ark Invest Dumps $17M In Coinbase Shares As The Exchange Grappled With Disruption Amid Bitcoin Rally
Via Benzinga
Cathie Wood's Ark Invest Sheds $9.3M Worth Of Coinbase Shares Amid Bitcoin Rally — Robinhood Stock Also Sold
Via Benzinga
Veracyte’s Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines
From Veracyte, Inc.
Via Business Wire
Cathie Wood's Ark Invest Offloads $6.9M Worth of Coinbase, Robinhood Shares Each Amid Searing Bitcoin Rally — Nvidia Stock Also Shed
Via Benzinga
7 Under-the-Radar Biotech Stocks Gearing Up for Liftoff
Via InvestorPlace
Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results
From Veracyte, Inc.
Via Business Wire
Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference
From Veracyte, Inc.
Via Business Wire
Earnings Scheduled For February 22, 2024
Via Benzinga
Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
From Veracyte, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.